Fibrinogen E fragment selectively disrupts the vasculature and inhibits the growth of tumours in a syngeneic murine model by Brown, N.J. et al.
Fibrinogen E fragment selectively disrupts the vasculature and
inhibits the growth of tumours in a syngeneic murine model
NJ Brown1, CA Staton2, GR Rodgers3, KP Corke2, JCE Underwood2 and CE Lewis*,2
1Microcirculation Research Unit, University of Sheffield Medical School, Sheffield S10 2RX, UK; 2Tumour Targeting Group, University of Sheffield Medical School,
Sheffield S10 2RX, UK; 3Institute for Cancer Studies, University of Sheffield Medical School, Sheffield S10 2RX, UK
We recently demonstrated that a fragment of human fibrinogen, fibrinogen E fragment, inhibits the migration and
differentiation of human endothelial cells in vitro. Here we show that it exerts similar effects on murine endothelial cells in vitro,
and selectively disrupts tumour endothelium in vivo, causing widespread intravascular thrombosis and retarding the growth of
CT26 tumours in a syngeneic murine model.
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Angiogenesis, the growth of new capillaries from an existing host
vascular bed, involves the migration, proliferation and differentia-
tion of endothelial cells and is crucial for the growth and
metastasis of tumours (Folkman, 1995). Various haemostatic
proteins regulate tumour angiogenesis (Browder et al, 2000),
including a 50 kDa proteolytic fragment (fibrinogen E fragment,
FgnE) of the blood clotting protein, fibrinogen, which inhibits
human endothelial cell activity in vitro (Bootle-Wilbraham et al,
2000).
Here we first established that FgnE also inhibits the activity of
murine human endothelial cells in vitro, and then examined the
effects of daily injections of FgnE on the vascular status and growth
of CT26 tumours in Balb/C mice in vivo (a syngeneic tumour
model).
MATERIALS AND METHODS
Cells and cell culture
The murine colonic adenocarcinoma cell line, CT26, is a N-nitro-
so-N-methylurethane induced Balb/C tumour and was a gift from
Professor Ian Hart, ICRF, London, UK. An SV40-transformed
murine endothelial cell line, SVEC4-10, was obtained from ATCC.
Both cell types were maintained in Dulbecco’s Minimal Eagles
Medium (DMEM), 10% foetal calf serum (FCS), 1% penicillin
and streptomycin in 5% CO2 in air at 378C.
Proteins and peptides
Human FgnE was purchased from Diagnostica Stago (Asnieres,
France). Recombinant human VEGF165 was purchased from R&D
Systems (Abingdon, UK).
In vitro assays
The MTT proliferation assay was used as described previously
(Liu et al, 1999) following the incubation of SVEC4-10 in
DMEM+10% FCS in the presence of 0, 10 or 100 nM FgnE
for 24, 48 and 96 h. The migration assay involved use of a
microchemotaxis chamber (Neuro Probe Inc, Cabin John, MD,
USA) with 8 mm pore size filter coated with collagen type IV
(Bootle-Wilbraham et al, 2000). Ten ng ml71 VEGF with or
without 10 or 100 nM FgnE were placed in the lower wells.
SVEC4-10 cells in DMEM containing 1% FCS were added to
the upper chamber for 4.5 h and then migrated cells on the
bottom of the filters fixed, stained and counted at 6160
magnification in three random fields per filter. The Matrigel
assay was performed as described in Donovan et al (2001).
SVEC4-10 cells were seeded onto wells coated with growth
factor-reduced (GF-reduced) Matrigel (Becton Dickinson
Labware, Bedford, MA, USA) and incubated for 6 h in
DMEM+1% FCS alone (control), or medium+10 ng ml71
VEGF+10 or 100 nM FgnE. Cells were then fixed, stained with
haematoxylin and eosin, visualized (at 640 magnification), and
tubule formation assessed in three randomly selected fields of
view per well using Scion Image software. Cell viability was
assessed by seeding SVEC4-10 cells in the absence or presence
of 0, 10 or 100 nM FgnE for 24 h (Bootle-Wilbraham et al,
2002) and adding propidium iodide prior to FACScanning using
Cell Quest software (Becton Dickinson).
In vivo study
All experiments were performed under HO Project Licence
Number PPL40/1557 (to NJ Brown) and conformed to the United
Kingdom Co-ordinating Committee on Cancer Research
(UKCCCR) Guidelines for the Welfare of Animals in Experimental
Neoplasia (as described in 1998 in Br J Cancer 77: 1 – 10). Animals
were anaesthetised by intraperitoneal injection of 1 : 1 diazepam
and hypnorm (Janssen, UK). Mice were then inoculated subcuta-
neously with 26106 ml71 in 100 ml viable CT26 cells. When
tumours had grown to 100 – 350 mm3, mice were injected i.p. daily
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for 8 days with FgnE (0.5 mg kg71; eight mice) or vehicle (phos-
phate buffered saline; seven mice). Assuming 50 – 100% absorption
from the peritoneum into the bloodstream, and a total blood
volume in mice of 2 ml, an injection of 0.5 mg kg71 FgnE was
calculated to result in a plasma concentration of 10 – 100 nM (i.e.
similar to the concentration used in our in vitro studies). Tumour
volumes were calculated daily using calipers (Grosios et al, 1999).
After 8 days, mice were killed and tumours and normal tissues
excised, divided into two halves and fixed in either: (i) 10% neutral
buffered formalin or (ii) zinc-based fixative (Beckstead, 1994), the
processed into paraffin wax.
Formalin-fixed sections were stained for H&E or Martius
yellow-brilliant crystal scarlet-soluble blue (MSB, a histological
stain for fibrin) (Lendrum et al, 1962). Using consecutive micro-
scopic fields, tumour necrosis was assessed semi-quantitatively
using a Chalkley grid method (% necrosis). Zinc-fixed sections
were exposed to a rat monoclonal anti-murine CD31 (1 : 100; Phar-
minogen, CA, USA) specific for endothelial cells, for 60 min at
room temperature, and immunoreactivity detected using the ABC
rat elite kit (Vector Laboratories, UK) and diaminobenzidine.
Maximal vascular density was quantified using the Chalkley grid
method (Leek et al, 1996).
Statistical analysis
Statistical analysis was performed using the Mann – Whitney U-test.
All data shown in Figures 1 – 3 are means+s.e.m. and representa-
tive data from one of three replicate experiments are shown.
RESULTS
In vitro assays
One hundred nM FgnE significantly (P50.05) inhibited the
proliferation of SVEC4-10 cells over 96 h in vitro (Figure 1).
VEGF-induced migration of SVEC4-10 across collagen-coated
filters was significantly (P50.01) inhibited by exposure to both
10 or 100 nM FgnE (Figure 2A). SVEC4-10 cells formed tubules
in the absence of VEGF, but this was significantly (P50.001)
enhanced by VEGF. Addition of FgnE (10 or 100 nM) also
significantly (P50.005) inhibited VEGF-stimulated tubule forma-
tion (Figure 2B). Neither dose of FgnE was cytotoxic for SVEC4-
10 cells.
In vivo studies
Control tumours grew steadily over the 8-day injection period but
FgnE injections significantly (P50.001) retarded the growth of
tumours from day 2 onwards (Figure 3). FgnE injections were well
tolerated in vivo with no significant effect on body weight or the
general well-being of the animals. A central area of necrosis
consisting of cell debris alone was evident in both control and
FgnE-treated tumours, but was significantly (P50.05) larger in
FgnE-treated mice (% necrosis: 7.8+0.9 for control versus
23.9+2.8 for FgnE-treated). No significant difference in microves-
sel counts was seen, although this was slightly higher in areas
abutting the central necrotic areas in FgnE-treated (6.5+0.9) than
control (4.8+0.5) tumours, because these vessels were distended,
lined with patchy, incomplete endothelial cells and filled with/or
surrounded by fibrin (Figure 3D) as seen by MSB staining (indicat-
ing that thrombus formation had occurred in these damaged
vessels). However, FgnE had no effect on the endothelium in the
normal tissues examined (lungs, liver and kidneys). Similar results
were obtained in three separate cohorts of animals.
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Figure 1 Effects of FgnE (10 and 100 nM) on the proliferation of SVEC4-
10 cells in vitro. *P50.05 w.r.t. the same time point for the relevant control
group.
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Figure 2 Inhibitory effects of FgnE on the (A) migration of, or (B) tubule
formation by, SVEC4-10 cells on growth factor-reduced Matrigel in vitro (in
the absence (control) or presence of 10 ng ml71 exogenous recombinant
VEGF). *P50.005 w.r.t. respective ‘no VEGF’ group, ^P50.01 w.r.t. re-
spective ‘no FgnE’ group.
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DISCUSSION
This study is the first to show that FgnE inhibits the proliferation,
migration and tubule formation of murine endothelial cells in vitro,
and causes widespread damage to blood vessels in CT26 tumours in
vivo. The resultant microvascular thrombosis and occlusion in
tumour blood vessels caused widespread destruction of tumour cells
and retarded tumour growth. The selective disruption of tumour
endothelium by FgnE indicates that this fragment may bind with
greater affinity to activated tumour endothelium than quiescent
endothelial cells in healthy tissues. However, further studies are
needed to show whether the inhibitory effects of FgnE on endothe-
lial cells in vitro contributed significantly to the anti-vascular effects
seen in vivo. It would also be interesting to determine whether high-
er doses of FgnE, or administration of FgnE by a different route
(e.g. intravenous) would enhance this anti-tumour effect.
The receptor(s) mediating the inhibitory effects of FgnE on
endothelial cells has/have yet to be identified. Previous studies have
shown that whole fibrinogen binds to various integrins on
endothelial cells via RGD motifs in the D-domain of the fibrinogen
molecule (Suehiro et al, 1997). However, FgnE lacks these domains,
so FgnE binding may involve one or more novel, non-RGD sites.
Interestingly, FgnE (100 nM) also significantly inhibited the prolif-
eration (but not the migration or viability) of CT26 cells and 3T3
fibroblasts over 96 h in our assays, suggesting that it may have a
direct effect on tumour cells in vivo (data not shown).
Taken together, these preliminary findings suggest that FgnE
could be used to selectively target blood vessels in tumours, causing
endothelial cell damage, triggering a haemostatic response (i.e.
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Figure 3 FgnE inhibition of the growth of CT26 tumours in Balb/C
mice. Mice were injected i.p. with PBS alone (control) or 0.5 mg kg71
FgnE in PBS for 8 days. Tumour volume was significantly (P50.05) re-
duced in FgnE-treated animals from day 2 of the injection period on-
wards.
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Figure 4 Effect of FgnE injection on the general histology and vascular endothelium of malignant and non-malignant murine tissues in vivo. CT26
tumours were excised from control (A,B) or FgnE-treated (C,D) mice and stained with haematoxlin and eosin, and morphology examined at
low magnification (A,C; bars=100 mm) or anti-murine CD31 (brown stain; see arrows) and viewed at higher magnification (B,D; bars=50 mm). Cells
in control tumours exhibited a compact, regular morphology (A) with vessels lined by a continuous single layer of endothelial cells (B). By contrast,
FgnE-treated tumours exhibited an increased levels of necrosis (see ‘N’ in D) and large distended vessels (as in C,D) lined with discontinuous en-
dothelial cells (see arrows in D). CD31-positive cells lining vessels in a range of non-malignant tissues (see arrows); lungs (E,H), lever (F,I) and kidneys
(G,J), from mice were unaffected by FgnE treatment (H,I and J) and resembled those from control (E,F and G) mice. Bar in J=50 mm (same mag-
nification in E – J).
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thrombosis), leading to inadequate perfusion and widespread
tumour cell death. This fragment may also exert a direct anti-
proliferative effect on some types of tumour cell, thereby contribut-
ing to retarded tumour growth by this second mechanism.
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